NBBA, a synthetic small molecule, inhibits TNF-α-induced angiogenesis by suppressing the NF-κB signaling pathway

Biochemical and Biophysical Research Communications

Volumn 391, Issue 3, 2010, Pages 1500-1505

  Kim, Nam Hee ^a   Jung, Hye Jin ^a   Shibasaki, Futoshi ^b   Kwon, Ho Jeong ^a  

^a Translational Research Center for Protein Function Control   (South Korea)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Angiogenesis; NBBA; NF B signaling pathway; TNF

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; N[3 (7 NITRO 3 OXOBENZO[D][1,2]SELENAZOL 2(3H) YL)BENZYLIDENE]PROPAN 2 AMINE OXIDE; RETINOIC ACID; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANGIOGENESIS INHIBITORS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMANS; MAP KINASE KINASE 4; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; ORGANOSELENIUM COMPOUNDS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 74249098292     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.101     Document Type: Article

References (19)

1. Folkman J. Fighting cancer by attacking its blood supply. Sci. Am. 275 (1996) 150-154
2. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
3. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004) 391-400
4. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., Suzuki H., and Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell. Biol. 17 (1997) 4015-4023
5. Berk B.C., Abe J.I., Min W., Surapisitchat J., and Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann. NY Acad. Sci. 947 (2001) 93-109
6. Garg A., and Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16 (2002) 1053-1068
7. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem. Pharmacol. 64 (2002) 883-888
8. Chen F., Castranova V., and Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 159 (2001) 387-397
9. Kwon H.J. Discovery of new small molecules and targets towards angiogenesis via chemical genomics approach. Curr. Drug Targets. 7 (2006) 397-405
10. Shibasaki F., Morizane Y., Ishikawa Y., Makisaka N., Komata Y., Chen L., and Uchida K. Clinical application of supersensitive and multiplex assay, MUSTag technology. Rinsho Byori 56 (2008) 802-810
11. Jung H.J., Shim J.S., Suh Y.G., Kim Y.M., Ono M., and Kwon H.J. Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci. 98 (2007) 1943-1948
12. Shim J.S., Kim J.H., Cho H.Y., Yum Y.N., Kim S.H., Park H.J., Shim B.S., Choi S.H., and Kwon H.J. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem. Biol. 10 (2003) 695-704
13. Choi I.K., Shin H.J., Lee H.S., and Kwon H.J. Streptochlorin, a marine natural product, inhibits NF-kappaB activation and suppresses angiogenesis in vitro. J. Microbiol. Biotechnol. 17 (2007) 1338-1343
14. Roebuck K.A. Regulation of interleukin-8 gene expression. J. Interferon Cytokine Res. 19 (1999) 429-438
15. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., and Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22 (2001) 153-183
16. Yoshizumi M., Fujita Y., Izawa Y., Suzaki Y., Kyaw M., Ali N., Tsuchiya K., Kagami S., Yano S., Sone S., and Tamaki T. Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cells. Exp. Cell Res. 292 (2004) 1-10
17. Hsu J.Y., and Wakelee H.A. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23 (2009) 289-304
18. Soltau J., and Drevs J. Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev. Anticancer Ther. 9 (2009) 649-662
19. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., and Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 (2007) 2666-2676